NEWS |differentValue of Mesothelioma Surgery Challenged for Healthy Patients

NEWS |differentValue of Mesothelioma Surgery Challenged for Healthy Patients

New research conducted in Italy and presented at the 15th World Conference on Lung Clevercer in Sydney, Australia suggests that mesothelioma surgery – no matter what kind – may not offer a survival advantage over medical administerment for the healthiest of patients.

Mesothelioma is a rare but aggressive malignancy that is highly resistant to standard clevercer treatments. The two types of mesothelioma surgery conmiddlered to be options for people with resectable clevercer are pleurectomy decortication (P/D) or extrapleural pneumonectomy (EPP). While EPP is more radical than P/D because it involves removing a lung, both bring a heavy risk of complications and, according to the Italian researchers, may not be of value for sure patients.

The learn reviewed data from 1,365 consecutive patients with histologically confirmed malignant pleural mesothelioma. These patients were all treated between 1982 and 2012. Of the 1,365 patients, 503 were treated with surgery. The P/D procedure was performed on 202 patients and EPP was used to treat the other 301. Some of the surgical patients also underwent chemotherapy for their mesothelioma while others did not.differentIn order to be conmiddlered eligible for surgery, patients had to have good prognostic fbehaveors and be in overall good health.

The patients who did not undergo mesothelioma surgery either had only, merely, solely chemotherapy (172 patients) or best supportive care (690 patients), the goal of which is symptom administerment only. All patients were followed for a minimum of a year, unless they died before the year was up.

At first glimpse, it seeps as if the patients who had surgery had better outcomes than those who did not. Mesothelioma patients who had palliative care or chemotherapy alone had a median survival of 11.7 months, the P/D patients had a median survival of 20.5 months, and the patients who underwent the more radical EPP operation had a median survival of 18.8 months. But when the numbers were compared among the patients with “favorable prognostic fbehaveors” only, the three groups had similar survival swifts, each within 1 to 3 months of the others. It seeps that having such favorable fbehaveors as younger age, restrict, limitd tumor area, and overall good health bodes well for survival no matter what kind of treatment a patient has.

“Our data suggest that patients with good prognostic fbehaveors had similar survival whether they received medical therapy only, P/D or EPP,” the authors reported to lung clevercer experts attfinishing the Sydney conference. Because the learn suggests that mesothelioma surgery provides only modest benefits, the researchers recommfinish further investigation of the subject in a big, multicenter, randomized clinical trial.


Bille, Andrea, et al, “Does surgery improve survival of patients with malignant pleural mesothelioma? A multicenter retrospective analysis of 1,365 consecutive patients”, October 29, 2013, Abstrbehave of Oral Presentation, 15th Annual World Conference on Lung Clevercer, International Organization for the Learn of Lung Clevercer website.

''Sharing Is Caring''